RNA, U1 small nuclear 56, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU1-56P profile across patient tissues and cancer cell-line models. RNU1-56P expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNU1-56P is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, RNU1-56P RNA expression shows 6,328 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight KIRC, and BRCA as cancer lineages where RNU1-56P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU1-56P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU1-56P survival associations across molecular data types. RNU1-56P RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU1-56P RNA expression–survival associations across cancer types. High RNU1-56P expression shows unfavorable associations in KIRC, LGG, CHOL, UCS and STAD, but favorable associations in CESC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RNU1-56P RNA expression.
This table summarizes RNU1-56P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU1-56P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU1-56P shows lower tumor expression in BRCA and higher tumor expression in KIRC and COAD. The BRCA box plot shows higher RNU1-56P RNA expression in normal versus tumor tissue (log2 FC = −0.570, t-test p = .001).
This table shows molecular features associated with RNU1-56P in patient tissues and cancer cell lines. In patient samples, RNU1-56P shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
